The Smallpox Vaccine stands as a historic triumph in the field of vaccinology, marking one of humanity's most significant victories over infectious disease. Developed in the late 18th century by Edward Jenner, the smallpox vaccine was the first successful vaccine ever created, paving the way for the eradication of smallpox, one of the deadliest diseases in human history. The smallpox vaccine is derived from the vaccinia virus, a related virus that belongs to the same family as the smallpox virus, Variola. Jenner discovered that individuals who had been infected with cowpox, a mild disease similar to smallpox, appeared to be protected against smallpox. Drawing on this observation, Jenner developed a vaccine by inoculating individuals with material from cowpox lesions, leading to immunity against smallpox.
The success of the smallpox vaccine revolutionized public health practices and laid the foundation for the development of other vaccines. Through widespread vaccination campaigns, smallpox was eventually eradicated from the world in 1980, making it the first and only human disease to be eradicated through vaccination. The smallpox vaccine's impact on global health cannot be overstated. Prior to its development, smallpox epidemics ravaged populations around the world, causing millions of deaths and leaving survivors scarred and disfigured. The vaccine's introduction led to a dramatic decline in smallpox cases and mortality rates, saving countless lives and sparing future generations from the devastation wrought by this deadly disease.
Although smallpox vaccination is no longer routinely administered due to the eradication of the disease, stocks of the vaccine are maintained for use in the event of a bioterrorism threat or outbreak. The smallpox vaccine continues to serve as a symbol of the power of vaccination to control and eliminate infectious diseases, inspiring ongoing efforts to develop vaccines against other deadly pathogens and protect global health.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia